Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
The widespread introduction of anti-HER2 agents has changed the natural course of Her2-positive breast cancer. The use of trastuzumab, and later dual anti-HER2 blockade with pertuzumab, in neoadjuvant regimens significantly increased the chances of complete cure. However, among patients with early a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6582 |
| _version_ | 1797841298872336384 |
|---|---|
| author | E. V. Lubennikova Ya. V. Vishnevskaya |
| author_facet | E. V. Lubennikova Ya. V. Vishnevskaya |
| author_sort | E. V. Lubennikova |
| collection | DOAJ |
| description | The widespread introduction of anti-HER2 agents has changed the natural course of Her2-positive breast cancer. The use of trastuzumab, and later dual anti-HER2 blockade with pertuzumab, in neoadjuvant regimens significantly increased the chances of complete cure. However, among patients with early and locally advanced forms of Her2-positive cancer, there is a cohort with an extremely unfavorable prognosis – tumors that have not achieved complete pathomorphological regression after neoadjuvant chemotherapy.The presence of a residual tumor in Her2-positive breast cancer has long been only a prognostically unfavorable factor without the potential to influence disease outcome. The results of the international phase III study KATHERINE, which demonstrated the high efficacy of post-adjuvant therapy with trastuzumab emtansine (T-DM1) in this patient cohort, have established a new standard of care. Due to T-DM1 adjuvant therapy, the possibility to significantly improve long-term results determined the predictive characteristics of the morphological response to the choice of treatment tactics, which became an important argument in favor of neoadjuvant therapy in patients with not only locally advanced but also primarily resectable Her2-positive breast cancer, followed by personalization of therapy.This article presents our own experience with post-neoadjuvant therapy with trastuzumab emtansine in a young patient with a residual tumor. The data of the main studies in early Her2-positive breast cancer are summarized. |
| first_indexed | 2024-04-09T16:28:44Z |
| format | Article |
| id | doaj.art-8801488b9a084c5e953dd4fc345e122a |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:28:44Z |
| publishDate | 2021-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-8801488b9a084c5e953dd4fc345e122a2023-04-23T06:57:11ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-12-01020687410.21518/2079-701X-2021-20-68-745943Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancerE. V. Lubennikova0Ya. V. Vishnevskaya1Blokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyThe widespread introduction of anti-HER2 agents has changed the natural course of Her2-positive breast cancer. The use of trastuzumab, and later dual anti-HER2 blockade with pertuzumab, in neoadjuvant regimens significantly increased the chances of complete cure. However, among patients with early and locally advanced forms of Her2-positive cancer, there is a cohort with an extremely unfavorable prognosis – tumors that have not achieved complete pathomorphological regression after neoadjuvant chemotherapy.The presence of a residual tumor in Her2-positive breast cancer has long been only a prognostically unfavorable factor without the potential to influence disease outcome. The results of the international phase III study KATHERINE, which demonstrated the high efficacy of post-adjuvant therapy with trastuzumab emtansine (T-DM1) in this patient cohort, have established a new standard of care. Due to T-DM1 adjuvant therapy, the possibility to significantly improve long-term results determined the predictive characteristics of the morphological response to the choice of treatment tactics, which became an important argument in favor of neoadjuvant therapy in patients with not only locally advanced but also primarily resectable Her2-positive breast cancer, followed by personalization of therapy.This article presents our own experience with post-neoadjuvant therapy with trastuzumab emtansine in a young patient with a residual tumor. The data of the main studies in early Her2-positive breast cancer are summarized.https://www.med-sovet.pro/jour/article/view/6582breast cancerher2-positive breast cancerneoadjuvant therapyadjuvant therapypostneoadjuvant therapytrastuzumab emtansinet-dm1trastuzumabpertuzumabkatherineidfsresidual tumorpathological regressionpcr |
| spellingShingle | E. V. Lubennikova Ya. V. Vishnevskaya Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer Медицинский совет breast cancer her2-positive breast cancer neoadjuvant therapy adjuvant therapy postneoadjuvant therapy trastuzumab emtansine t-dm1 trastuzumab pertuzumab katherine idfs residual tumor pathological regression pcr |
| title | Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer |
| title_full | Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer |
| title_fullStr | Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer |
| title_full_unstemmed | Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer |
| title_short | Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer |
| title_sort | role of post neoadjuvant therapy with trastuzumab emtansine in her2 positive breast cancer |
| topic | breast cancer her2-positive breast cancer neoadjuvant therapy adjuvant therapy postneoadjuvant therapy trastuzumab emtansine t-dm1 trastuzumab pertuzumab katherine idfs residual tumor pathological regression pcr |
| url | https://www.med-sovet.pro/jour/article/view/6582 |
| work_keys_str_mv | AT evlubennikova roleofpostneoadjuvanttherapywithtrastuzumabemtansineinher2positivebreastcancer AT yavvishnevskaya roleofpostneoadjuvanttherapywithtrastuzumabemtansineinher2positivebreastcancer |